Health City adds AI imaging tools for brain and prostate care

Health City Cayman Islands will roll out AI-assisted imaging at its Camana Bay hospital to help doctors measure and monitor neurological disease and prostate cancer. The new NeuroQuant suite is designed to add objective data to MRI and CT review without replacing physician judgment.

Why it matters: - Health City Cayman Islands is adding quantitative imaging tools that can support earlier tracking of neurological disease and prostate cancer. - The technology is designed to give clinicians objective measurements that can be compared across scans over time. - The service could help patients with memory concerns, multiple sclerosis, brain tumors and prostate cancer get more detailed follow-up imaging.

What happened: - Health City Cayman Islands will introduce AI-assisted imaging technology at its Camana Bay hospital. - The hospital acquired the full NeuroQuant suite. - The system is intended to support assessment and monitoring of conditions including Alzheimer’s disease, multiple sclerosis, brain tumors and prostate cancer. - The service will be available at Health City’s Camana Bay location.

The details: - NeuroQuant analyzes medical images and produces objective measurements to support a radiologist’s interpretation. - The software processes compatible MRI and CT studies. - Depending on the application, the system identifies and outlines brain structures, lesions or tumor regions. - The software measures volume and generates reports and visual maps for clinical review. - The measurements are meant to give physicians additional information alongside what appears on the scan. - An initial focus will be brain health and cognitive assessment. - NeuroQuant measures the volume of specific brain structures and compares results with reference data. - The brain-volume analysis supports assessment of brain atrophy associated with Alzheimer’s disease and other neurodegenerative conditions. - Follow-up scans can show changes over time. - The suite also includes tools to track multiple sclerosis lesions and brain tumor volumes. - The platform supports prostate cancer assessment and treatment planning. - The system can monitor imaging changes associated with certain Alzheimer’s therapies. - Automated CT analysis adds information for clinical assessment and follow-up. - The technology is meant to complement clinical judgment. - The software does not independently diagnose disease or replace a physician or radiologist. - Patients should speak with their treating physician to determine whether quantitative imaging is appropriate. - People with persistent memory or cognitive concerns are encouraged to begin with their general practitioner.

Between the lines: - Health City is positioning AI imaging as a decision-support tool, not a standalone diagnostic product. - The emphasis on quantitative comparisons suggests a push toward more standardized follow-up for complex conditions. - The initial focus on brain health indicates neurology and cognitive care are the first likely use cases before broader adoption.

What's next: - Patients at Camana Bay can begin accessing the service through their treating physician. - Clinicians will use the new imaging data alongside symptoms, medical history and other test results. - Health City is directing patients with memory concerns to primary care first, which suggests a referral path into specialized imaging when appropriate.

The bottom line: - Health City is expanding from visual image review to AI-assisted measurement, aiming to make brain and prostate imaging more precise and more useful over time.